Cancer chemotherapy and pharmacology
Journal
Overview
publication venue for
-
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency.
1990
-
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer..
95.
2025
-
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma..
92.
2023
-
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma..
87.
2021
-
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer..
84.
2019
-
Neoadjuvant chemotherapy in patients with advanced endometrial cancer..
84.
2019
-
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma..
83.
2018
-
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies..
82.
2018
-
Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer..
82.
2018
-
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies..
81.
2018
-
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment..
80.
2017
-
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms..
80.
2017
-
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)..
79.
2017
-
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70..
77.
2015
-
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies..
75.
2015
-
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma..
75.
2015
-
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors..
75.
2015
-
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma..
74.
2014
-
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma..
73.
2013
-
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)..
73.
2013
-
Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers..
72.
2013
-
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)..
72.
2013
-
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer..
72.
2013
-
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab..
72.
2013
-
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies..
71.
2013
-
The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model..
71.
2013
-
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial..
71.
2012
-
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)..
70.
2012
-
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53..
70.
2012
-
Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats..
69.
2012
-
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors..
70.
2012
-
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors..
69.
2011
-
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial..
69.
2011
-
A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors..
69.
2011
-
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma..
68.
2011
-
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies..
68.
2011
-
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion..
68.
2011
-
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer..
68.
2010
-
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer..
68.
2010
-
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer..
67.
2010
-
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer..
66.
2010
-
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol..
66.
2010
-
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies..
66.
2010
-
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors..
65.
2009
-
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients..
65.
2009
-
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies..
64.
2009
-
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors..
64.
2009
-
BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line..
63.
2008
-
NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells..
63.
2008
-
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer..
62.
2008
-
Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells..
62.
2007
-
Influence of carboplatin infusion on osteosarcoma blood flow..
62.
2007
-
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors..
59.
2006
-
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer..
58.
2006
-
Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes..
57.
2005
-
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer..
57.
2005
-
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors..
57.
2005
-
Phase I study of green tea extract in patients with advanced lung cancer..
55.
2004
-
Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults..
53.
2004
-
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors..
52.
2003
-
A phase I trial of perillyl alcohol in patients with advanced solid tumors..
51.
2003
-
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity..
50.
2002
-
Population pharmacokinetics of the novel anticancer agent KRN7000..
49.
2002
-
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer..
49.
2001
-
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy..
48 Suppl 1.
2001
-
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility..
46.
2000
-
SEREX analysis of gastric cancer antigens..
46 Suppl.
2000
-
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis..
45.
2000
-
Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion..
40.
1997
-
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer..
40.
1997
-
Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents..
40.
1997
-
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule..
35.
1995
-
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study..
36.
1995
-
Modulation of all-trans retinoic acid pharmacokinetics by liarozole..
34.
1994
-
Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy..
31.
1993
-
Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside..
29.
1992
-
Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group..
29.
1992
-
Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response..
30.
1992
-
Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells..
28.
1991
-
Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung..
28.
1991
-
Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872..
28.
1991
-
Phase II study of divided-dose vinblastine in advanced breast cancer patients..
21.
1988
-
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease..
18.
1986
-
Phase I/II trial of intravesical methotrexate for superficial bladder tumors..
18.
1986
-
Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone..
17.
1986
-
Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma..
14.
1985
-
Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer..
12.
1984
-
Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors..
8.
1982
-
Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)..
7.
1982
-
Metformin and pancreatic cancer: Is there a role?
2016
-
In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors.
1999
Identity
ISO Abbreviation
-
Cancer Chemother Pharmacol
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)